Icos Corp. is unwilling to give up on testing its LeukArrest monoclonal antibody in patients with hemorrhagic shock even after seeing no benefit in most end points in a 150-patient Phase II trial and despite having multiple ongoing trials in less difficult indications.

ICOS (Bothell, Wash.) last week reported that the anti-CD11/CD18 MAb did not reduce the amount of non-blood fluids administered in the first 24 hours nor reduce the extent of multiple organ failure, the two primary end points, in patients with